Ellansé publication listing
PCL-based dermal fillers offer advantages over the NASHA-based dermal fillers, in terms of both cosmetic longevity and efficiency. 17% less injection volume was required with Ellansé to reach optimal cosmetic effects compared to the NASHA dermal filler. Galadari H, et al. A randomised, prospective, blinded, split-face, single-centre study comparing polycaprolactone to hyaluronic acid for treatment of nasolabial folds. J Cosmet Dermatol. 2015;14(1):27-32. 13 months after an Ellansé-M injection, PCL microspheres were surrounded by collagen deposition and a mild fibroblastic and histiocytic tissue response was seen. This confirms that PCL particles are maintained in their original state at least 13 months post-injection in human tissue.
A novel dermal filler and promising new device with immediate aesthetic correction and sustained results due to the formation of new collagen. The PCL microspheres in the filler trigger a natural response within the human body to stimulate neocollagenesis.
Gritzalas K. Preliminary results in using a new dermal filler based on poly-caprolactone. Eur J Aesth Med Dermatol. 2011;1:22-26.
Mixing lidocaine into the PCL-based dermal filler can be safely performed without causing harmful changes to the physical properties of the original dermal filler. Adding up to 0.3% of the anaesthetic agent lidocaine will not substantially affect the filler’s characteristics, confirming the usability of this mixture in clinical practice. De Melo F, Marijnissen-Hofsté J. Investigation of physical properties of a polycaprolactone dermal filler when mixed with lidocaine and lidocaine/ epinephrine. Dermatol Ther. 2012;2:13-22. Ellansé is safe, well tolerated and effective for hand rejuvenation with high patient satisfaction and retention rates. Ellansé provides an immediate effect and offers a good choice based on its longevity.
Kim JA, Van Abel D. Neocollagenesis in human tissue injected with a polycaprolactone-based dermal filler. J Cosmet Laser Ther. 2015;17(2):99-101.
Ellansé shows advantages over an HA dermal filler when applied to the forehead. Ellansé has significantly higher elasticity (G’) compared to the HA dermal filler and the non-crosslinked CMC molecules make it smoother and easier to inject. These neocollagenesis benefits are long term and the natural looking results last for at least 24 months.
Figueiredo VM. A five-patient prospective pilot study of a polycaprolactone based dermal filler for hand rejuvenation. J Cosmet Dermatol. 2013;12:73-77.
Bae B, et al. Safety and long-term efficacy of forehead contouring with a polycaprolactone-based dermal filler. Dermatol Surg. 2016;42(11):1256-60.
Ellansé-S and Ellansé-M are safe and have sustained efficacy and high patient satisfaction results over 24 months. Ellansé is a unique option for patients seeking longer lasting but non-permanent results. Moers-Carpi MM, Sherwood S. Polycaprolactone for the correction of nasolabial folds: a 24-month, prospective, randomized, controlled clinical trial. Dermatol Surg. 2013;39 (3 Pt 1):457-63. The PCL microspheres of Ellansé-M are still present 21 months post-injection. The PCL microspheres are embedded in a collagen scaffold of primarily type-1 collagen fibres.
A multinational, multidisciplinary group of experts, plastic surgeons and dermatologists have developed recommendations on the injection techniques of Ellansé. These recommendations provide a guideline for physicians who wish to perform safe and efficacious treatment for volume augmentation and rejuvenation of the face and hands. De Melo F et al. Recommendations for volume augmentation and rejuvenation of the face and hands with the new generation polycaprolactone-based collagen stimulator (Ellansé®). Clinical, Cosmetic and Investigational Dermatology 2017:10 431-440. A 46-year-old Asian woman was treated with Ellansé to restore facial volume loss. Facial images after Ellansé treatment revealed a more reverse triangular shaped and in proportion rejuvenated face coupled with the improvement of a downward shift of soft tissue
Nicolau P, Marijnissen-Hofsté J. Neocollagenesis after injection of a polycaprolactone based dermal filler in a rabbit. Eur.J.Aesth Medicine and Dermatology. 2013;3:19-26.
Lin SL. Polycaprolactone facial volume restoration of a 46-year-old Asian woman: A case report. J Cosmet Dermatol. 2018; 1-5.
Model is not an actual patient.
28 ELLANSÉ PRACTITIONER GUIDE
29 ELLANSÉ PRACTITIONER GUIDE
Made with FlippingBook interactive PDF creator